Non-essential activities and new regulatory submissions are on hold until a federal government funding agreement is reached.
FDA will continue with some operations during the January 2018 federal government shutdown, but activity related to fiscal year (FY) 2018 business, including regulatory submissions for FY 2018 that require a fee payment, are on hold. The agency noted in a statement and on Twitter that it will continue to support activities funded by carryover user fee balances, which would allow the agency to review some medical products during the shutdown.
In a statement, the agency said agency operations would “continue to the extent permitted by law, such as activities necessary to address imminent threats to the safety of human life and activities funded by carryover user fee funds.”
More than 40% of FDA’s workforce has been furloughed.
Mission critical, public health activities that will continue during the shutdown include maintaining core functions to handle and respond to emergencies, supporting high-risk food and medical product recalls, pursuing criminal and certain civil investigations that threaten public health, screening food and medical product imports, and addressing the ongoing IV saline shortage that was exacerbated by the 2017 hurricanes in Puerto Rico, FDA reports. The agency is also monitoring widespread flu activity.
The federal government shut down on Jan. 20, 2018 after Congress failed to pass a budget appropriation or a continuing resolution to keep the government open.
Sources: FDAScott Gottlieb Twitter Feed
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.